+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Prostate Cancer Nuclear Medicine Diagnostics Market by Type (PET, SPECT), Product (C-11, F-18, Ga 68 PSMA) - Forecast 2024-2030- Product Image
Global Prostate Cancer Nuclear Medicine Diagnostics Market by Type (PET, SPECT), Product (C-11, F-18, Ga 68 PSMA) - Forecast 2024-2030- Product Image
Sale

Global Prostate Cancer Nuclear Medicine Diagnostics Market by Type (PET, SPECT), Product (C-11, F-18, Ga 68 PSMA) - Forecast 2024-2030

  • PDF Icon

    Report

  • 196 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5639599
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Prostate Cancer Nuclear Medicine Diagnostics Market size was estimated at USD 1.03 billion in 2023, USD 1.15 billion in 2024, and is expected to grow at a CAGR of 12.76% to reach USD 2.39 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Prostate Cancer Nuclear Medicine Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Prostate Cancer Nuclear Medicine Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Prostate Cancer Nuclear Medicine Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Blue Earth Diagnostics, Inc., Bracco Diagnostic Inc., Cardinal Health, Inc, General Electric Company, Global Medical Solutions LLC, Jubilant DraxImage, Inc., Jubilant Pharma Limited, Lantheus Holdings, Inc., NCM-USA LLC, NorthStar Medical Radioisotopes, LLC, Novartis AG, Petnet Solutions Inc. by Siemens Healthcare Private Limited, SHINE Medical Technologies, LLC, and Telix Pharmaceuticals Limited.

Market Segmentation & Coverage

This research report categorizes the Prostate Cancer Nuclear Medicine Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • PET
    • SPECT
  • Product
    • C-11
    • F-18
    • Ga 68 PSMA
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Prostate Cancer Nuclear Medicine Diagnostics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Prostate Cancer Nuclear Medicine Diagnostics Market?
  3. What are the technology trends and regulatory frameworks in the Prostate Cancer Nuclear Medicine Diagnostics Market?
  4. What is the market share of the leading vendors in the Prostate Cancer Nuclear Medicine Diagnostics Market?
  5. Which modes and strategic moves are suitable for entering the Prostate Cancer Nuclear Medicine Diagnostics Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Prostate Cancer Nuclear Medicine Diagnostics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidences of prostate cancer worldwide necessitates early diagnosis
5.1.1.2. Potential development of novel imaging agents to enhance prostate cancer detection
5.1.1.3. Increasing adoption of diagnostic procedures such as PET diagnostic tool attributed to higher accuracy
5.1.2. Restraints
5.1.2.1. Relatively high cost of the testing
5.1.3. Opportunities
5.1.3.1. Availability of reimbursement policies in developed and developing economies
5.1.3.2. Rising research for the development of innovative imaging agents
5.1.4. Challenges
5.1.4.1. Stringent regulations pertinent to storage and use of radiopharmaceuticals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Prostate Cancer Nuclear Medicine Diagnostics Market, by Type
6.1. Introduction
6.2. PET
6.3. SPECT
7. Prostate Cancer Nuclear Medicine Diagnostics Market, by Product
7.1. Introduction
7.2. C-11
7.3. F-18
7.4. Ga 68 PSMA
8. Americas Prostate Cancer Nuclear Medicine Diagnostics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Bayer AG
12.1.2. Blue Earth Diagnostics, Inc.
12.1.3. Bracco Diagnostic Inc.
12.1.4. Cardinal Health, Inc
12.1.5. General Electric Company
12.1.6. Global Medical Solutions LLC
12.1.7. Jubilant DraxImage, Inc.
12.1.8. Jubilant Pharma Limited
12.1.9. Lantheus Holdings, Inc.
12.1.10. NCM-USA LLC
12.1.11. NorthStar Medical Radioisotopes, LLC
12.1.12. Novartis AG
12.1.13. Petnet Solutions Inc. by Siemens Healthcare Private Limited
12.1.14. SHINE Medical Technologies, LLC
12.1.15. Telix Pharmaceuticals Limited
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET DYNAMICS
FIGURE 7. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 8. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 10. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 12. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 14. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 20. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 9. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY C-11, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY F-18, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GA 68 PSMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 13. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 15. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 16. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 17. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 18. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 19. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 20. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 21. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 22. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 26. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. AUSTRALIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 31. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 33. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 34. INDIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 35. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. INDONESIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 37. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. JAPAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 39. MALAYSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. MALAYSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 41. PHILIPPINES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. PHILIPPINES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 43. SINGAPORE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. SINGAPORE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 45. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. SOUTH KOREA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 47. TAIWAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. TAIWAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 49. THAILAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. THAILAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 51. VIETNAM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. VIETNAM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. DENMARK PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. EGYPT PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 60. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. FINLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 62. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 66. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. ISRAEL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. NETHERLANDS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 72. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. NIGERIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 74. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. NORWAY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. POLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 78. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. QATAR PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 82. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 84. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 88. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. SWEDEN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 90. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. SWITZERLAND PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. TURKEY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 94. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 99. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 100. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET LICENSE & PRICING

Companies Mentioned

  • Bayer AG
  • Blue Earth Diagnostics, Inc.
  • Bracco Diagnostic Inc.
  • Cardinal Health, Inc
  • General Electric Company
  • Global Medical Solutions LLC
  • Jubilant DraxImage, Inc.
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • NCM-USA LLC
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • Petnet Solutions Inc. by Siemens Healthcare Private Limited
  • SHINE Medical Technologies, LLC
  • Telix Pharmaceuticals Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages196
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.39 Billion
Compound Annual Growth Rate12.7%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Global Prostate Cancer Nuclear Medicine Diagnostics Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global Prostate Cancer Nuclear Medicine Diagnostics Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 172 Pages
  • Global
From
Nuclear Medicine Radioisotopes - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Nuclear Medicine Radioisotopes - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 119 Pages
  • Global
From
Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy)), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy)), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 170 Pages
  • Global
From
Global Nuclear Medicine Therapeutics Market Analysis & Forecast 2024-2034: Market By Type; By Application; By End-user; and By Region - Product Image

Global Nuclear Medicine Therapeutics Market Analysis & Forecast 2024-2034: Market By Type; By Application; By End-user; and By Region

  • Report
  • 145 Pages
  • Global
From
Nuclear Medicine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Nuclear Medicine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 190 Pages
  • Global
From

About the Prostate Cancer Nuclear Medicine Diagnostics Market

Prostate cancer nuclear medicine diagnostics is a segment within the broader field of medical diagnostics focused on using nuclear medicine techniques to detect and evaluate prostate cancer. Nuclear medicine is a medical specialty that employs small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and sometimes treat diseases. In prostate cancer diagnosis, these radiopharmaceuticals are designed to target specific molecules associated with the presence of cancer cells, such as the prostate-specific membrane antigen (PSMA). Imaging technologies like Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) are utilized in conjunction with these radiotracers to visualize the distribution of the radioactive material within the prostate gland and surrounding tissues. This enables physicians to detect the presence and extent of prostate cancer, thereby guiding treatment decisions and prognostication. Key players in the prostate cancer nuclear medicine diagnostics market include companies that specialize in the production of radiopharmaceuticals, as well as those that manufacture the imaging equipment used in the diagnostic process. Some prominent companies in this market are Advanced Accelerator Applications (a subsidiary of Novartis), Blue Earth Diagnostics (a Bracco company), Progenics Pharmaceuticals (part of Lantheus Medical Imaging), IsoRay Medical, and Bayer AG. These companies engage in research and development to improve the specificity and sensitivity of nuclear diagnostic agents for prostate cancer and strive to create advanced imaging systems for more precise disease characterization. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.